<DOC>
	<DOC>NCT02062294</DOC>
	<brief_summary>This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.</brief_summary>
	<brief_title>An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>Liver transplant recipients, &gt;/= 16 years of age Transplantation between January 2004 and June 2009 CMV seronegative recipient (R) who received a liver transplant from a seropositive donor (D+) Valganciclovir therapy for at least 70 days beginning within 10 days post transplantation Assessment of CMV disease status within the first 6 months post transplantation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>